表紙
市場調查報告書

EpiCast Report:血友病的流行病學預測 (2024年)

Hemophilia: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 344637
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:血友病的流行病學預測 (2024年) Hemophilia: Epidemiology Forecast to 2028
出版日期: 2019年07月31日內容資訊: 英文 48 Pages
簡介

所謂血友病是指X連鎖性·遺傳性的出血障礙,特徵是凝血因子中VII因子(A型血友病的情況) 或是IX因子 (B型血友病的情況)的生產、機能障礙的結果所造成凝血障礙。血友病患者(雖然也要看嚴重度)的關節、肌肉、軟組織、黏膜內部會自然發生出血,或是伴隨內傷或外傷的大量出血。全球9個國家確診的A、B型血友病患者數在2014年為60,671人(其中美國約佔28%),預測到2024年前將達到61,954人。由於血友病是遺傳性疾病,需要一輩子接受治療,但近年來由於高齡化及高血壓患者的增加,預測今後將需要血友病患者高血壓的對策。

本報告提供全球主要9個國家 (美國,德國,法國,義大利,西班牙,英國,日本,阿根廷,中國) 的A、B型血友病的發病情形與今後預測相關分析,提供您疾病的特徵,及目前患病者的發病情形,今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 相關分析
  • 出版預定的相關分析

第3章 流行病學的預測

  • 疾病的背景情況
  • 風險要素和共生病症
  • 全世界的趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • A型血友病的流行病學的預測 (今後11年份)
    • 確診的患病人數
    • 確診的患病人數:各年齡
    • 確診的患病人數:男女
    • 確診的患病人數 (年齡已調整)
  • B型血友病的流行病學的預測 (今後11年份)
    • 確診的患病人數
    • 確診的患病人數:各年齡
    • 確診的患病人數:男女
    • 確診的患病人數 (年齡已調整)
  • A、B型血友病的流行病學的預測 (今後11年份)
    • 確診的患病人數
    • 確診的患病人數:男女
  • 議論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER207-19

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (Hemophilia A) or factor IX (Hemophilia B). Hemophilia is a rare, genetic, potentially life-threatening bleeding disorder. The clinical presentation of hemophilia ranges from mild, to moderate, to severe stages, depending on the residual level of the circulating factor.

The diagnosed prevalent cases of hemophilia in the US are likely to exceed that of China over the next decade, with 18,723 cases in the US in 2028 as compared to 14,186 cases in China in 2028, due to higher hemophilia knowledge in the US as compared to China.

Diagnosed prevalent cases of Hemophilia A and Hemophilia B is forecasts to increase across the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and China), from 67,051 cases in 2018 and 67,678 cases in 2028, at an Annual Growth Rate (AGR) of 0.09%. The US will have the highest number of diagnosed prevalent cases of hemophilia A and Hemophilia B among the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and China), while Spain will have the lowest.

Epidemiologists forecast an increase in the diagnosed prevalent cases of acquired hemophilia from 2,163 diagnosed prevalent cases in 2018 to 2,215 diagnosed prevalent cases in 2028, with an AGR of 0.24% during the forecast period. China will have the highest number of diagnosed prevalent cases of acquired hemophilia among the eight major markets, while Spain will have the lowest.

The latest report "Hemophilia: Epidemiology Forecast to 2028", reveals that the relatively stable trend in the diagnosed prevalent cases of hemophilia over the next decade is partly attributable to changing population demographics in the next ten years. The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and Hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.

Scope

  • The Hemophilia Epidemiology Report provides an overview of the risk factors and global trends of hemophilia in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.
  • The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
  • Understand magnitude of hemophilia population by severity.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hemophilia: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
    • 3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
    • 3.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia
  • 3.5 Epidemiological Forecast for Hemophilia A (2018-2028)
    • 3.5.1 Diagnosed Prevalent Cases of Hemophilia A
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
    • 3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
    • 3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
  • 3.6 Epidemiological Forecast for Hemophilia B (2018-2028)
    • 3.6.1 Diagnosed Prevalent Cases of Hemophilia B
    • 3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
    • 3.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
    • 3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
    • 3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
  • 3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018-2028)
    • 3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
    • 3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
    • 3.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
  • 3.8 Discussion
    • 3.8.1 Epidemiological Forecast Insight
    • 3.8.2 Limitations of Analysis
    • 3.8.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Relationship of Bleeding Severity with Clotting Factor Level.
  • Table 2: Comorbidities for Hemophilia

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, All Ages, 2018 and 2028
  • Figure 3: 8MM, Diagnose
Back to Top